Latest Health News

Metro Performance Glass reported a surprising 157% jump in net profit for H1 2025, even as revenue fell 5%, raising questions about underlying business dynamics.

Island Pharmaceuticals has secured membership in the Medical Countermeasures Coalition, positioning its antiviral Galidesivir for critical US government stockpiling and regulatory milestones.

Atomic Eagle Ltd, formerly known as Tombador Iron Limited, will have its trading suspension lifted and be reinstated to quotation on the ASX starting 24 November 2025 after meeting key compliance requirements.

The Foreign Investment Review Board has formally objected to Cosette Pharmaceuticals’ proposed acquisition of Mayne Pharma, casting serious doubt on the deal’s future and prompting Mayne to explore alternative paths.

Verbrec Limited has reported a strong FY2025 with record margins and resumed dividend payments after more than a decade, alongside strategic moves including a key acquisition and divestment.

Earlypay Limited has extended its on-market share buy-back program for another 12 months, allowing the company to repurchase up to 10% of its ordinary shares without shareholder approval.

The Star Entertainment Group has secured crucial regulatory approvals to convert a $300 million strategic investment by Bally’s Corporation and Investment Holdings into equity, setting the stage for board changes and a path toward financial recovery.

Kogan.com Ltd delivered strong FY25 results with significant customer growth and improved cash flow, while Mighty Ape embarks on a strategic recovery aiming for profitability in FY26.

RLF AgTech reports a robust 34% increase in Australian revenue for the four months to October 2025, driven by stronger distributor engagement and promising trial results. The company is poised for growth as it enters its critical January–June 2026 sales season with an expanded national footprint.

OMG Group has secured its maiden purchase order for premium SANDAI matcha in Australia, marking a promising start to a new high-margin revenue channel ahead of FY26.

Little Green Pharma Ltd reported a 9.6% revenue increase to $19.2 million and slashed its net loss by 73% in the half-year ending September 2025, driven by strong growth in European medicinal cannabis markets.

ECS Botanics has achieved a milestone with direct-to-consumer sales exceeding 60% of total revenue, driven by the launch of innovative sugar-free THC gummies and a strategic distribution partnership.